BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 29946182)

  • 1. Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer.
    Chen JH; Yang JL; Chou CY; Wang JY; Hung CC
    Sci Rep; 2018 Jun; 8(1):9686. PubMed ID: 29946182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
    Shao T; Zhao M; Liang L; Tang W
    Front Immunol; 2022; 13():948597. PubMed ID: 36389713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
    Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
    Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy.
    Pang LL; Gan JD; Huang YH; Liao J; Zhuang WT; Ali WA; Hong SD; Zhang L; Fang WF
    BMC Cancer; 2023 Jan; 23(1):72. PubMed ID: 36670414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
    Passiglia F; Galvano A; Rizzo S; Incorvaia L; Listì A; Bazan V; Russo A
    Int J Cancer; 2018 Mar; 142(6):1277-1284. PubMed ID: 29080213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC).
    Xu Z; Li T; Hu X; Hao X; Xing P; Li J
    Thorac Cancer; 2021 Sep; 12(17):2360-2368. PubMed ID: 34268872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis.
    Peng TR; Lin HH; Tsai FP; Wu TW
    Thorac Cancer; 2021 Nov; 12(21):2873-2885. PubMed ID: 34545685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Chen R; Hou X; Yang L; Zhao D
    Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
    Medicine (Baltimore); 2018 Aug; 97(33):e11936. PubMed ID: 30113497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials.
    Gu J; Shi L; Jiang X; Wen J; Zheng X; Cai H; Zhang W
    Cancer Immunol Immunother; 2022 Sep; 71(9):2239-2254. PubMed ID: 35124713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    Rizvi NA; Hellmann MD; Brahmer JR; Juergens RA; Borghaei H; Gettinger S; Chow LQ; Gerber DE; Laurie SA; Goldman JW; Shepherd FA; Chen AC; Shen Y; Nathan FE; Harbison CT; Antonia S
    J Clin Oncol; 2016 Sep; 34(25):2969-79. PubMed ID: 27354481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy and Safety of TKIs Alone or in Combination With Antiangiogenic Agents in Advanced EGFR-Mutated NSCLC as the First-Line Treatment: A Systematic Review and Meta-Analysis.
    Zhang S; Li S; Liu J; Yang C; Zhang L; Bao H; Cheng Y
    Clin Lung Cancer; 2022 Mar; 23(2):159-169. PubMed ID: 34247986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.
    Siciliano MA; Caridà G; Ciliberto D; d'Apolito M; Pelaia C; Caracciolo D; Riillo C; Correale P; Galvano A; Russo A; Barbieri V; Tassone P; Tagliaferri P
    ESMO Open; 2022 Jun; 7(3):100465. PubMed ID: 35427835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
    Manegold C
    Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
    Chen J; Wang J; Xu H
    Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials.
    Yin Q; Dai L; Sun R; Ke P; Liu L; Jiang B
    Cancer Res Treat; 2022 Jul; 54(3):803-816. PubMed ID: 34696564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.